Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful treatment with afatinib after grade 3 hepatotoxicity induced by both gefitinib and erlotinib in EGFR mutation-positive non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands) - 1 Sept 2016

Zenke Yoshitaka, Umemura Shigeki, Sugiyama Eri, Kirita Keisuke, Matsumoto Shingo, Yoh Kiyotaka, Niho Seiji, Ohmatsu Hironobu, Goto Koichi

Abstract excerpt

Hepatotoxicity is a major cause of the withdrawal of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) when treating EGFR mutation-positive non-small cell lung cancer (NSCLC). We report a case in which gefitinib- and elrotinib-induced severe hepatotoxicity arose in a patient with the uridine diphosphate glucuronosyltransferase isoform 1A1 (UGT1A1) and cytochrome p450 3A5 (CYP3A5) poor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemical and Drug Induced Liver Injury
Share to Cytochrome P-450 CYP3A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gefitinib

Share to Glucuronosyltransferase

Share to Pharmacogenetics

Share to Pharmacogenomic Variants

Share to Quinazolines

Share to Retreatment

Source

Identifiers

PMID: 27565905
DOI: 10.1016/j.lungcan.2016.05.002

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful treatment with afatinib after grade 3 hepatotoxicity induced by both gefitinib and erlotinib in EGFR mutation-positive non-small cell lung cancer.PMID 27565905Read ↗

Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations.Semantic proximity Read ↗

Safe and successful treatment with afatinib in three postoperative non-small cell lung cancer patients with recurrences following gefitinib/erlotinib-induced hepatotoxicity.Semantic proximity Read ↗

Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.Semantic proximity Read ↗

Osimertinib-related liver injury with successful osimertinib rechallenge: A case report.Semantic proximity Read ↗

Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters.Semantic proximity Read ↗

Metabolic complete tumor response in a patient with epidermal growth factor receptor mutant non-small cell lung cancer treated with a reduced dose of afatinib.Semantic proximity Read ↗

Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism.Semantic proximity Read ↗

Influence of genetic polymorphisms on gefitinib pharmacokinetics and adverse drug reactions in non-small cell lung cancer patients.Semantic proximity Read ↗

Interindividual Variability in Cytochrome P450 3A and 1A Activity Influences Sunitinib Metabolism and BioactivationSemantic proximity Read ↗

Comparison of adverse events of erlotinib with those of gefitinib in patients with non-small cell lung cancer: a case-control study in a Japanese population.Semantic proximity Read ↗

Severe hepatotoxicity during treatment with capmatinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.